|
20 documents found matching dt:brochure.
|
|
of 2
Prev
Next
|
|
|
|
Showing 1-10 of 20 documents
|
1.
CV Card
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
ONCE DAILY
IN RESPONSE TO YOUR QUESTIONS
CARDIOVASCULAR
SYSTEM
u nwm
(rofecoxib)
CLINICAL PROFILE IN OSTEOARTHRITIS STUDIES
pgNbr=1
• M*;x
(rofecœdty IN OA STUDIES
BASELINE CARDIOVASCULAR (CV)
Of Risk Factors Percentage of Patients at Baseline*
Hypertension
39%
Hypercholesterolemia
11%
Current smoker
14%
Diabetes
7%
History of angina/coronary artery disease (CAD)
5%
History of myocardial infarction (Ml)
3%
Congestive heart failure (CHF)
1%
'Mean age: 63 yeais (range:. 39-93). Gender: 70% female, 30% male.
VIOXX is indicated for:
Relief of the signs aré symptoms of osteoarthritis (CA).
The management of acute pain in adults (see CLINICAL STUDIES).
Treatment of primary dysmenorrhea.
Selected safety information
VIOXX is contraindicated in patients with known hypersensitivity to rofecoxib or any other component of VOOC
VIOXX should not be given to patiente who have experienced asthma, urticaria, or allergic-type reactions after taking
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx10r10
|
|
| |
2.
Cardiovascular system
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
It'
Ñ RESPONSE TO YOUR QUESTIONS
ONCE DAILY
Tj[|
m
i
CARDIOVASCULAR
F-iyr
%
CLINICAL PROFILE IN OSTEOARTHRITIS STUDIES
t?M ¦
;i's; .. ¦:¦¦:¦ ::^
PLAINTIFF'S EXHIBIT
"¦¦ ,--*V>'tiS''.*S-
PLAINTIFF EXHIBIT 1202
pgNbr=1
(rofecoxib)
IN ©A STUDIES
CHÊtmcmmmcs1
O/ Risk Factors
Percentage
of Patients at Baseline*
Hypertension
39% ,
Hypercholesterolemia
11%
Current smoker
14%
Diabetes
7%
History of angina/coronary artery disease (CAD)
5%
History of myocardial infarction (Ml)
3%
Congestive heart failure
(CHF)
1%
'Mean age: 63 years (range:.39-93). Gender: 70% female, 30% male.
VIOXX is indicated for:
Relief of the signs and symptoms of osteoarthritis (OA).
The management of acute pain in adults (see CLINICAL STUDIES).
Treatment of primary dysmenorrhea.
Selected safety information
VIOXX is contraindicated in patients with known hypersensitivity to rofecoxib or any other component of VIOXX.
VIOXX should not be given to patiente who h
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx07m10
|
|
| |
3.
Sales Brochure
|
Document Date:
|
19050623
|
|
Search Terms in Context:
|
rriV[7>\ VIOXX50 mg vs oxycodone/acetaminophen 5/325 mg
i^H^M
For the management of acute pain in many adult patients
POWER AGAINST*
w
pgNbr=1
viosm
rofecoxib)
(rofecoxib
In two single-dose studies of postoperative dental pain in adults'
SUPERIOR PAIN RELIEF OVER 6 HOURS'
0)
8
•s
Q-
C
1.5
v 1.0
0.0
XX 50 mg vs Oxycodone/Acetaminop
VIOXX 50 mg (n=90) ¦ Oxycodone/Acetaminophen 5/325 mg (n=91) ¦ Placebo (n=31)
0.5
4 5
Hours Postdose
More Relief
Less Relief
Two randomized, placebo- and active-comparator-controlled, double-blind trials to investigate the analgesic effects of VIOXX 50 mg (single oral dose) compared with oxycodone 5 mg with acetaminophen 325 mg (single oral dose) and placebo in the treatment of postoperative dental pain.
' Primary end point was total pain relief over 6 hours after dosing (TOPAR6). Efficacy measurements performed at 0.5, I, 2, 3, 4, 5, 6, 8, 12, and 24 hours: Pain Relief (0 = None, 1 = A Little, 2 = Some, 3 = A Lot, 4 = Comple
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx13i10
|
|
| |
4.
Booklet re company policies
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
Dear Merck Colleagues,
Think, just for a moment, about the contributions that this Company has made to society over the past century. Think of the lives that have been saved, lengthened or significantly improved as a result of our efforts. Think of the families who have enjoyed additional years with brothers, sisters, parents and children because of our products and services.
When we reflect on the life-saving and life-enhancing role our Company plays all over the world, we feel an enormous sense of pride — and a great sense of responsibility to ensure that this organization is preserved for future generations.
"We try never to forget that medicine is for the people. It is not for
the profits. The profits follow, and if we have remembered that,
they have never failed to appear. "
— George W. Merck
These words were written many years ago in a vastly different world, yet the values they embody continue to guide our Company every day, around the world. Technical advancements are superseded and marketing
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx07k10
|
|
| |
5.
Questions and Answers about Postmenopausal Hormone Therapy and Breast Health [With Annotations]
|
Document Date:
|
00000000
|
|
Page Count:
|
6
|
|
Search Terms in Context:
|
^ I've heard that HRT might make it harder to detect breast cancer. Is that true?
&4. In some women, HRT increases something called "breast density." In general, breast density is higher in younger women whose breasts have relatively less fat and more lean tissue than older women. HRT acts on breast density by maintaining it at—or restoring to—premenopausal levels.
Breast density affects how a woman's breasts appear in a mammogram, and very dense breasts can mate mammograms somewhat hard to read. However, there is no evidence that HRT use affects breast cancer detectioa In fact, researchers have shown that breast cancers in HRT users are found at similar—and in some studies earlier—stages than in nonusers. If HRT use makes breast cancer harder to detect, wc would expect the research to indicate the exact opposite.
% What if I'm diagnosed with breast cancer while I'm taking HRT. WiU HRT make the disease harder to treat?
¦s4. Studies have found that breast cancer patients using HRT at the time the
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/rsc37b10
|
|
| |
6.
Cardiovascular System: Clinical Profile in Osteoarthritis Studies
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
IN RESPONSE TO YOUR QUESTIONS
CARDIOVASCULAR
SYSTEM
(rofecoxib)
CLINICAL PROFILE
IN OSTEOARTHRITIS
STUDIES
v110aw
(rofeco)ib) IN OA STUDIES
BASELINE CARDIOVASCULAR (CLI
CHARACTERISTJCS'
CV Risk Factors Percentage of Patients at Baseline*
Hypertension 39%
Hypercholesterolemia 11%
Current smoker 14%
Diabetes 7%
History of angina/coronary artery disease (CAD) 5%
History of myocardial 3%
infarction (MI)
Congestive heart failure (CHF) 1%
*Mean age: 63 years (range: 39-93). Gender: 70%female, 30% male.
VIOXX is indicated for:
Relief of the signs and symptoms of osteoarthritis (OA).
The management of acute pain in adults (see CLINICAL STUDIES).
Treatment of primary dysmenorrhea.
Selected safety information
VIOXX is contraindicated in patients with known hypersensitivrty to rofecoxib or any other
component of VIOXX.
VIOXX should not be given to patients who have experienced asthma, urticaria, or
allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory
drugs (NSAIDs). Severe, rare
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/njb00a10
|
|
| |
7.
PI9183810
|
Document Date:
|
20020411
|
|
Search Terms in Context:
|
^ MERCK & CO., INC
Whitehouse Station, NJ D8889, USA
VIOXX®
{rofecoxib tablets and oral suspension)
DESCRIPTION
VIOXX* (rofecoxib) is described fonyl)phcnyl]-3-phcnvl-2(-&W)-furaronc.
structure:
chemically as 4-[4-(nrethvlsul-It has tho following chemical
o.
\\
9183S10 VIOXX'* (rofecoxib tablets and o al suspension]
Cytochrome P45D plays a miner role in metabolism of rofecoxib. InhibiLiuii u\ CYP 3A d^LiviLy by adii iiiiüLrdLiun uT ktjL'jcuiid^ulti 400 my
daily does no: affect rofecoxib disposition. However, inducion of general
hepatic metabolic activity by administration ot the non-specitic inducer rifampin 600mg daily produces a 50% decrease in rofecoxib plasma concentrations. (Also see Drug interactions.)
Excrétion
ílüfecüxib is eliminated predominantly by hepatic metabolism with little [<\%) unchanged drug recovered ir the urine. Followirg a single radiolabeled dose of 125mgr approximately 72% of the dose was excrered into the urine as metabolites and 14% in the fe
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx16l10
|
|
| |
8.
Vioxx label - PI 9183811
|
Document Date:
|
20020401
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
^ MERCK&CO.,INC.
Whitehouse Station, NJ 08889, USA
VIOXX®
{rafee ox ib tablets and oral suspension)
DESCRIPTION
VIOXX* (loTecuxib) is desciibed chemically as 4-[4-(inelliyli;ul-fonyl)phenyl|-3-phenyl-2(5tf)-fuTanone. It has the following chemical structure:
9183811 VIQXXMrofecoxibtablets and oral suspension!
Cytochrome P450 plays a minor rulü in iiiuLabulisin ol rufycoxib. Inhibition of CYP 3A activity by administration of ketoconazole 400mg daily does not affect rofecoxib disposition. However, induction of general hBpatic metabolic activity by administration of the non-specific inducer rifampin 600 mg daily produces a 50% decrease in rofecoxib plasma concentrations. (Also see Drug Interactions.] Exemtion
Rofecoxib is eliminated predominantly by hepatic metabolism with little (<1%) unchanged drug recovered in the urine. Following a single radiolabeled dose of 125nig, approximately 72% of the dose was excreted into the urine as metabolites and 14% in the feces as unchanged drug.
The plasma clear
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx01m10
|
|
| |
9.
Vioxx label description
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
MBKK&CajNC
West Point. PA 19486; USA
VIOXX®
|rof ecoxib tablets and oral suspension)
KSCHFIrON. ;.
¦ VIO)Oe,|rbfeeoml)tisdeœribedchérTrâHym*^lmethyl-sulfünyllphenviVJiJhenyl-IlSH^furanone. h has the following chemical structure:
Rofecoxib is a white to off-white to light yellow powder. K is sparingly soluble in acetone, »lightly soluble in methanol and isopropyl acetate, very slightly soluble In ethancl, practically insoluble in octanol, and insoluble in water. The empirical formula for rofecoxib is CitHhOjS, and the molecular weigh« is 314J8. "
Each tablât of VIOXX for oral administration contains either 12.5 or 25 mg of rofecoxib and the following inactive ingredients: eroscamiellose »odium, hydroxypropyi cellulose, lacios«, magnesium stéarate., microcrystailine cellulose, and ye How 1er rie oxid a.
Each 5 ml of the oral suspension contains either 12-6 or • 25 mg of rofecoxib and the following inactive ingredients: citric
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx00z10
|
|
| |
10.
Vioxx label description
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
« MERCK & CO., INC.
Whitchouse Station, NJ 08889, USA
VIOXX®
(rofecoxib tablets and oral suspension)
DESCRIPTION
VIOXX* (rofecoxib) is described chemically as 4-[4-(methyl-sulfonyl)phenvN-3-plienyl-2Ì5/V)-furanone. It has the follow-ingchemical structure:
Rofecoxib is a white to aff-whïte to light yellow powder. It is sparingly soluble in acetone, slightly soluble in methanol and isopropyl acetate, vary slightly soluble in ethanol, practically insolnhle in octanol, and insoluble in water. I he empirical fnr-mula for rofecoxib is C17H11O4S, and the molecular weight ie 314.36.
Each tablet of VIOXX fororal administration contains either 12.5 or 25 mg of rofecoxib and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose, magnesium stéarate, macrocrystalline cellulose, and yellow ferric oxide.
Each 5 ml_ of the oral suspension contains either 12.5 or 25 mg of rofecoxib and the following inactive Ingredients: citric acid (monohydrate), sodîum citrate (dihydrate), sorbi
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx01d10
|
|
| |
|
Prev
Next
|
